RxDoctor Payments Data

Jolene Knight

Psychiatric/Mental Health · Mastic Beach, NYNPI 1912255415

Payments from drug & device makers

$1,579in general payments, 2019–2025

Across 38 payments — averaging $41.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$487
  • Neurocrine Biosciences, Inc.$287
  • Lundbeck LLC$246
  • Alkermes, Inc.$120
  • Axsome Therapeutics, Inc.$118
  • Eisai Inc.$118
  • plus $203 from 4 others

What the payments were for

  • Food & beverage$1,579100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,579 in reported general payments places this provider in the 75th percentile of 2,385 psychiatric/mental health providers in New York.

See all psychiatric/mental health providers in New York

Medicare billing

Part B allowed, 2024
$208,821
Medicare patients
239
Services billed
2,132

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole115$296,999
NamzaricMemantine Hcl/Donepezil Hcl38$47,335
TrintellixVortioxetine Hydrobromide12$16,018
Memantine Hcl ErMemantine Hcl86$13,392
QelbreeViloxazine Hcl16$12,736
Venlafaxine Hcl ErVenlafaxine Hcl170$6,078
Divalproex Sodium161$3,859
Quetiapine Fumarate125$3,480
Sertraline Hcl100$2,786
Desvenlafaxine Succinate ErDesvenlafaxine Succinate24$2,740
Mirtazapine67$2,113
Donepezil Hcl151$2,105
Modafinil37$1,550
Duloxetine Hcl33$1,389
Escitalopram Oxalate86$1,061

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$487$296,999115 claims
AbbVieNamzaric$20$47,33538 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,385 psychiatric/mental health providers in New York.

Other psychiatric/mental health in Mastic Beach

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →